Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.79 |
| ▸ | CHRNA3 | P32297 | 13/20 | 0.79 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.79 |
| ▸ | CHRNB3 | Q05901 | 13/20 | 0.79 |
| ▸ | CHRNA6 | Q15825 | 13/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14211345 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL3805279 | 0.83 | CHRNB2 (0.60) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1722528 | 0.80 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1978271 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL12895626 | 0.79 | MEN1 (0.69) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14845706 | 0.79 | MEN1 (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211200 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1462933 | 0.77 | CHRNB2 (0.70) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL27429184 | 0.77 | MEN1 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1464721 | 0.76 | CHRNA4 (0.68) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA3, CHRNA6 | CHRNB2 9/4885CHRNA3 2/4885CHRNA4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.